01.31.2025
Fast Track Initiative (FTI) has made a follow-on investment in Neusignal Therapeutics (CEO: Yoshifumi Yoshida; Headquarters: Tokyo, Japan; hereinafter referred to as ‘Neusignal’), a startup dedicated to developing treatments for Alzheimer’s disease. This additional funding is part of Neusignal’s Series A round, bringing the total raised to approximately 1.15B JPY. Makoto Takeuchi, Executive Vice President of FTI, serves as an external BoD member for Neusignal, while Hiroko Kimura, Principal at FTI, serves as the company’s Auditor.
Neusignal is dedicated to developing groundbreaking therapies aimed at treating the rapidly increasing global prevalence of Alzheimer’s disease. The company is currently advancing its candidate compounds, which hold promise in slowing disease progression. However, challenges such as treatment management complexities, high healthcare costs, and patient eligibility continue to spark debate. Neusignal aims to overcome these obstacles and deliver transformative therapies to those in need.
With this new investment, Neusignal plans to provide compounds for an upcoming investigator-initiated Phase 1 clinical trial, followed by a company-led clinical trial. Additionally, the company will begin preparations for a Phase 1b trial in the U.S.
FTI has been supporting Neusignal since its inception, providing hands-on support through its seed and current funding rounds.
Neusignal has also been selected for the AMED “Strengthening Program for Pharmaceutical Startup Ecosystem”, receiving a non-dilitive grant of 1.1B JPY. With this support, Neusignal’s total fundraising in this Series A round reaches 2.2B JPY.
About Neusignal Therapeutics
Neusignal Therapeutics is a pioneering biotechnology company based in Tokyo, Japan, focused on the development of innovative therapies for Alzheimer’s disease. Founded as a spin-off from Tohoku University, Neusignal is dedicated to advancing novel drug candidates aimed at slowing the progression of Alzheimer’s, a condition that is rapidly increasing worldwide. With a commitment to addressing the complex challenges of treatment management, high healthcare costs, and patient eligibility, Neusignal strives to bring transformative solutions to those affected by Alzheimer’s. The company is preparing for clinical trials, with plans for both domestic and international development.
About Fast Track Initiative:
Established in 2004, Fast Track Initiative, Inc. (FTI) is a life science venture capital firm focusing its investments on early-stage startups with a strong focus on biotech and therapeutics. FTI has a strict mission to make a ground-breaking impact on the quality of our life and human wellness through investments across a broad range of areas in the life science community including therapeutics, diagnostics, digital health, healthcare services, and more. The company provides valuable, hands-on support to its 30+ portfolio companies through business and R&D strategy, partnering, investor syndication, and more, including access to its network of professionals in Japan.
Visit https://us.fasttrackinitiative.com for more details, or follow us on LinkedIn: https://www.linkedin.com/company/fast-track-initiative/
Media Contact:
For press inquiries or investor inquiries, please email: message.us@fasttrackinitiative.com
